Tedisamil
From Wikipedia, the free encyclopedia
| Tedisamil | |
|---|---|
 |
|
| IUPAC name | 3,7-bis(cyclopropylmethyl)spiro[3,7-diazabicyclo [3.3.1]nonane-9,1'-cyclopentane] |
| Identifiers | |
| CAS number | [90961-53-8] |
| PubChem | |
| SMILES | C1CCC2(C1)C3CN(CC2CN(C3)CC4CC4)CC5CC5 |
| Properties | |
| Molecular formula | C19H32N2 |
| Molar mass | 288.470 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references |
|
Tedisamil (planned trade name Pulzium) is an investigational drug for atrial fibrillation and atrial flutter. It is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administration.
On April 25, 2007, Solvay submitted a New Drug Application for tedisamil, and on December 12, 2007, the Cardio-Renal Advisory Committee of the FDA voted against approval of tedisamil, at this time, requesting that Solvay Pharmaceuticals provides additional information to the FDA.[1]
[edit] References
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
